Galectin Therapeutics to Webcast Corporate Update

NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business portion of its 2016 Annual Meeting of Stockholders. Peter Traber, M.D., president, chief executive officer and chief medical officer, will provide an overview of the progress achieved over the past year, as well as the Company’s plans and strategy for the upcoming year, especially its seminal NASH-CX Trial. The webcast is expected to commence at approximately 1:30 p.m. ET on Thursday, December 15, 2016.

The webcast can be accessed via the investor relations portion of the Galectin Therapeutics website at http://investor.galectintherapeutics.com/ . The webcast may also be accessed directly via the following link: https://dentons.adobeconnect.com/galt_board/ . The presentation may also be heard via teleconference by dialing 866-225-1342 (within the United States). A list of international dial-in numbers can be found here . The passcode for participants is 8620018752. Please log in approximately 10 minutes before the event to ensure a timely connection.

The webcast will also be archived on the Company's website.

About Galectin Therapeutics Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contact Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com